PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecula...
Guardado en:
Autores principales: | Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
K63-linked ubiquitylation induces global sequestration of mitochondria
por: Thibaud J. C. Richard, et al.
Publicado: (2020) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021) -
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Maria Gonzalez-Cao, et al.
Publicado: (2021) -
Metsäbiomassan estimointi optimoidulla laserkeilaus- ja ilmakuva-aineistolla
por: Sakari Tuominen, et al.
Publicado: (2014) -
Miehittämättömät lentolaitteet metsien kaukokartoituksessa
por: Sakari Tuominen, et al.
Publicado: (2018)